Pacira BioSciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Pacira BioSciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pacira BioSciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pacira BioSciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Pacira BioSciences Inc (Pacira) is a pharmaceutical company that offers non-opioid pain management and regenerative health solutions. It mainly researches, develops, and commercializes innovative pain therapies based on its proprietary pMVL drug delivery technology. The company's products include bupivacaine liposome injectable suspension, triamcinolone acetonide extended-release injectable suspension, PCRX-201 (enekinragene inzadenovec) and drug delivery devices through the brands Exparel, Zilretta, and Iovera. The products find applications in postsurgical, musculoskeletal, and chronic pain management. It also sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US, Germany and the UK. Pacira is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
2000 Sierra Point Parkway, Suite 900, Brisbane, California, 94005
Website
www.pacira.com
Telephone
1 302 6587581
No of Employees
825
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PCRX (NASD)
Revenue (2024)
$726.4M
3.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
107.1%
(2024 vs 2023)
Market Cap*
$1.0B
Net Profit Margin (2024)
XYZ
106.8%
(2024 vs 2023)
* As of and is in US$
Pacira BioSciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Bupivacaine Liposome Injectable Suspension | - |
| Triamcinolone Acetonide Extended-Release Injectable Suspension | EXPAREL |
| Enekinragene Inzadenovec | Zilretta |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company entered into an agreement to sell iovera business to Zimmer Biomet Holdings, Inc., a medical technology leader. |
| 2026 | Contracts/Agreements | In January, the company entered into an agreement with LG Chem to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. |
| 2025 | Contracts/Agreements | In November, the company signed a worldwide license and collaboration agreement with AmacaThera to develop and commercialize of AMT-143. |
Competitor Comparison
| Key Parameters | Pacira BioSciences Inc | Roche Holding AG | Biogen Inc | Napp Pharmaceuticals Ltd | DURECT Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United Kingdom | United States of America |
| City | Brisbane | Basel | Cambridge | Cambridge | Cupertino |
| State/Province | California | Basel-Stadt | Massachusetts | England | California |
| No. of Employees | 825 | 112,774 | 7,500 | 31 | 13 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank D. Lee | Chief Executive Officer; Director | Executive Board | 2024 | 58 |
| Laura Brege | Chair | Executive Board | 2025 | 68 |
| Shawn Cross | Chief Financial Officer | Senior Management | 2024 | 58 |
| Kristen Williams | Secretary; Chief Administrative Officer | Senior Management | 2014 | 52 |
| Jonathan Slonin | Chief Medical Officer | Senior Management | 2023 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer